Prasugrel is associated with the best balance of efficacy and safety among P2Y₁₂ inhibitors among patients undergoing PCI, a large-scale meta-analysis suggests.

According to the findings, prasugrel was linked with a lower rate of major adverse cardiovascular events (MACE) than both ticagrelor and clopidogrel, with particularly reduced rates of myocardial infarction and stent thrombosis.

Researchers also found a higher risk of major bleeding with ticagrelor compared to clopidogrel, driven by higher intracranial haemorrhage.

“These results indicate that prasugrel provides the optimal balance for efficacy and safety in patients after PCI,” the study authors concluded, in a paper published in JAMA Cardiology [link here].

The analysis included data from 15 randomised clinical trials involving 48,904 patients (mean age, 63.2 years; 27.3% female).

Among the key findings:

• Compared with clopidogrel, prasugrel was associated with a lower risk of MACE (OR 0.80), driven by lower myocardial infarction (OR 0.71) and stent thrombosis (OR 0.48) rates.
• MACE was not significantly reduced with ticagrelor compared with clopidogrel, although there was lower risk of stent thrombosis (OR 0.73).
• Prasugrel was also associated with a lower MACE risk compared with ticagrelor (OR 0.83), driven by reductions in myocardial infarction (OR 0.78) and stent thrombosis (OR 0.66).
• Ticagrelor was associated with a higher risk of major bleeding versus clopidogrel (OR 1.24), driven by increased intracranial haemorrhage (OR 1.89).

Current international guidelines, including those from the European Society of Cardiology and NICE, broadly support dual antiplatelet therapy with aspirin plus a P2Y₁₂ inhibitor following PCI in patients with acute coronary syndromes, with ticagrelor or prasugrel generally preferred over clopidogrel unless contraindicated or in patients with increased bleeding risk.

The findings sit alongside previous head-to-head and landmark trials. The PLATO trial established ticagrelor’s edge over clopidogrel for composite ischaemic outcomes, while the TRITON-TIMI 38 study showed reduced cardiovascular events with prasugrel compared with clopidogrel, although both caused an increase in bleeding.

More recently, the ISAR-REACT 5 trial reported lower rates of cardiovascular events with prasugrel compared with ticagrelor, while TUXEDO-2 did not demonstrate non-inferiority of ticagrelor versus prasugrel in a high-risk diabetic PCI population.

The authors noted that the present analysis should be interpreted in the context of several important limitations, including its reliance on trial-level rather than patient-level data, and that definitions of MACE, major bleeding, and stent thrombosis varied across the trials.